Literature DB >> 2964862

Activated T lymphocytes in uveitis.

J Deschênes1, D H Char, S Kaleta.   

Abstract

Two colour flow cytometry techniques were used to assess the activation stages of peripheral and intraocular T lymphocytes in uveitis. Increased numbers of T lymphocytes bearing the interleukin-2 (IL-2) receptors were found in intraocular fluids or peripheral blood or both of 35/51 patients with uveitis. This increased expression of IL-2 receptors on lymphocytes correlated with increased expression of other early T lymphocyte activation markers, HLA-DR and L-35. Both T helper cells (Leu-3A+) and suppressor cells (Leu 2A+) were activated in vivo. A positive correlation was seen between lymphocyte activation and clinical uveitis activity. In idiopathic uveitis activation of Leu-3A lymphocytes (helper/inducer) was significantly increased, and intraocular activation of the Leu-2A lymphocytes (cytotoxic/suppressor) was significantly decreased. These data show that some patients with idiopathic uveitis have a perturbation of T helper cells. Twenty-two of 31 patients with idiopathic uveitis, not associated with systemic disease, had increased peripheral T lymphocyte activation. This finding indicates that in some inflammations believed to be restricted to the eye an abnormal systemic immune activation exists.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2964862      PMCID: PMC1041377          DOI: 10.1136/bjo.72.2.83

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

1.  Immune complexes in uveitis.

Authors:  D H Char; P Stein; R Masi; M Christensen
Journal:  Am J Ophthalmol       Date:  1979-05       Impact factor: 5.258

2.  T lymphocyte subsets in uveitis.

Authors:  R B Nussenblatt; M Salinas-Carmona; W Leake; I Scher
Journal:  Am J Ophthalmol       Date:  1983-05       Impact factor: 5.258

3.  Microtechniques for flow cytometric analysis of aqueous humor lymphocytes.

Authors:  W R Freeman; D H Char; M R Garavoy; H Lyon
Journal:  J Immunol Methods       Date:  1984-10-26       Impact factor: 2.303

4.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

5.  A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor.

Authors:  W J Leonard; J M Depper; T Uchiyama; K A Smith; T A Waldmann; W C Greene
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

6.  Functional significance of Tac antigen expressed on activated human T lymphocytes: Tac antigen interacts with T cell growth factor in cellular proliferation.

Authors:  T Miyawaki; A Yachie; N Uwadana; S Ohzeki; T Nagaoki; N Taniguchi
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

7.  T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat.

Authors:  R R Caspi; F G Roberge; C G McAllister; M el-Saied; T Kuwabara; I Gery; E Hanna; R B Nussenblatt
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

8.  Immunologic analysis of intraocular mononuclear cell infiltrates in uveitis.

Authors:  H J Kaplan; J C Waldrep; J K Nicholson; D Gordon
Journal:  Arch Ophthalmol       Date:  1984-04

9.  New concepts in the control of ocular inflammation.

Authors:  P I Murray; A H Rahi
Journal:  Trans Ophthalmol Soc U K       Date:  1985

10.  Serum immunoglobulins and uveitis.

Authors:  L S Kahn; T F Schlaegel; J C Weber; A Biegel
Journal:  Arch Ophthalmol       Date:  1983-03
View more
  24 in total

1.  Characterization of phenotype and cytokine profiles of T cell lines derived from vitreous humour in ocular inflammation in man.

Authors:  M Muhaya; V L Calder; H M Towler; G Jolly; M McLauchlan; S Lightman
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

2.  Soluble ICAM-1 serum levels in patients with intermediate uveitis.

Authors:  A M Klok; L Luyendijk; M J Zaal; A Rothova; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

3.  Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis.

Authors:  C C Murphy; L Duncan; J V Forrester; A D Dick
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

4.  Aqueous humor IL-8, IL-10, and VEGF levels in Fuchs' uveitis syndrome and Behçet's uveitis.

Authors:  Mert Simsek; Pinar Cakar Ozdal; Filiz Akbiyik; Mehmet Citirik; Nilufer Berker; Yasemin Ozdamar Erol; Pelin Yilmazbas
Journal:  Int Ophthalmol       Date:  2019-05-07       Impact factor: 2.031

Review 5.  Endogenous posterior uveitis.

Authors:  J V Forrester
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

Review 6.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

Review 7.  Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis?

Authors:  A D Dick
Journal:  Br J Ophthalmol       Date:  1995-01       Impact factor: 4.638

8.  Interleukin 4, IgG and oligoclonal IgG in aqueous humor of cataract patients.

Authors:  N Stambuk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-09       Impact factor: 3.117

9.  The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Behçet's uveitis.

Authors:  H G Yu; D S Lee; J M Seo; J K Ahn; Y S Yu; W J Lee; H Chung
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  Soluble intercellular adhesion molecule-1 (sICAM-1) as a marker of disease relapse in idiopathic uveoretinitis.

Authors:  A G Zaman; C Edelsten; M R Stanford; E M Graham; B A Ellis; H Direskeneli; D P D'Cruz; G R Hughes; D C Dumonde; G R Wallace
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.